UB Paderborn / Katalog / Suche / in CDI

128PD EGFR, KRAS, PIK3CA MUTATIONS AND RESPONSE TO TYROSINE KINASE INHIBITORS (TKIS) IN ADVANCED NSCLC PATIENTS

Lung cancer (Amsterdam, Netherlands), 2009, Vol.64, p.S54-S54

2009

Volltextzugriff (PDF)

P1.01-65 Immune Gene Expression, Bayesian Network and Genetic Mutation Analysis in Advanced NSCLC Patients Treated with Immunotherapy

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S384-S385

2019

Volltextzugriff (PDF)

9081 A phase II retrospective trial of Carboplatin (CBDCA) and Alimta in refractory non-small cell lung cancer (NSCLC) with genetic polymorphisms analysis

European journal of cancer supplements, 2009, Vol.7 (2), p.529-529

2009

Volltextzugriff (PDF)

9046 A phase II retrospective trial of Platinum/Gemcitabine (P/G)-based in first line treatment of advanced NSCLC with genetic polymorphisms analysis

European journal of cancer supplements, 2009, Vol.7 (2), p.519-519

2009

Volltextzugriff (PDF)

9050 NSCLC in never smokers, a different disease – a single institution retrospective evaluation

European journal of cancer supplements, 2009, Vol.7 (2), p.520-520

2009

Volltextzugriff (PDF)

9162 EGFR, KRAS, PIK3CA mutations and response to tyrosine kinase inhibitors (TKIs) in advanced NSCLC patients

European journal of cancer supplements, 2009, Vol.7 (2), p.554-554

2009

Volltextzugriff (PDF)

6522 POSTER EGFR mutations and response to TKIs therapy in NSCLC patients pre-treated with chemotherapy

European journal of cancer supplements, 2007, Vol.5 (4), p.364-364

2007

Volltextzugriff (PDF)

Interobserver reproducibility of immunohistochemical HER-2/neu assessment in human breast cancer : An update from INQAT round III

The International journal of biological markers, 2005-07, Vol.20 (3), p.189-194

2005

Volltextzugriff (PDF)

MYC and human telomerase gene (TERC) gene copy number gain in resected in non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.10580-10580

2011

Volltextzugriff (PDF)

Insulin-like growth factor receptor-1 (IGF1R) and epidermal growth factor receptor (EGFR) amplification and expression in surgically resected NSCLC

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.10519-10519

2011

Volltextzugriff (PDF)

Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of MET, EGFR, KRAS, and PIK3CA mutations

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.7562-7562

2010

Volltextzugriff (PDF)

Mutational analysis of KRAS, BRAF, and p53 genes in borderline and malignant epithelial ovarian tumors

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e21069-e21069

2010

Volltextzugriff (PDF)

Correlation of polymorphisms of genes involved in platinum/gemcitabine (P/G)-based metabolism with toxicity and clinical response in patients (pts) with advanced non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.8093-8093

2009

Volltextzugriff (PDF)

Effect of genetic polymorphisms on toxicity and survival in advanced non-small cell lung cancer (NSCLC) patients (pts) treated with carboplatin (CBDCA) and pemetrexed disodium regimen

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.e19028-e19028

2009

Volltextzugriff (PDF)

HER2, EGFR, PIK3CA mutations in HER2+ metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T): Incidence and correlation with response

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.1031-1031

2008

Volltextzugriff (PDF)

EGFR, KRAS, PIK3CA mutations and response to tyrosine kinase inhibitors (TKIs) in advanced NSCLC patients

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.22003-22003

2008

Volltextzugriff (PDF)

Relevance of p53, bcl-2 and Rb expression on resistance to cisplatin-based chemotherapy in advanced non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2003, Vol.39 (1), p.41-48

2003

Volltextzugriff (PDF)

Evaluation of HER-2 in serum and tissue: correlation with clinical-pathological parameters and outcome in early stage breast cancer (BC) patients (pts)

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.20066-20066

2006

Volltextzugriff (PDF)

Biological prognostic factors for early stage completely resected non-small cell lung cancer

Journal of surgical oncology, 2000-05, Vol.74 (1), p.53-60

2000

Volltextzugriff (PDF)

PD-157 Serum EGFR in patients with non-small cell lung cancer(NSCLC) treated with gefitinib

Lung cancer (Amsterdam, Netherlands), 2005-07, Vol.49, p.S112-S112

2005

Volltextzugriff (PDF)

O-112 Microsatellite alterations and P53 mutations in tumor and plasma DNA of resected non small cell lung cancer (NSCLC) patients. (A study of the Perugia Multidisciplinary team for thoracic tumors)

Lung cancer (Amsterdam, Netherlands), 2005-07, Vol.49, p.S39-S40

2005

Volltextzugriff (PDF)

Arteriosclerotic Carotid Lesions in Hyperlipoproteinemia

Angiology, 1986-11, Vol.37 (11), p.797-800

1986

Volltextzugriff (PDF)

p53 overexpression predicts the resistance to chemotherapy in advanced non small cell lung cancer (NSCLC)

European journal of cancer (1990), 2001-04, Vol.37, p.S118-S118

2001

Volltextzugriff (PDF)

Biological prognostic factors for early stage completely resected non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2000-09, Vol.29 (1), p.133-133

2000

Volltextzugriff (PDF)

HDL2- and HDL3-cholesterol in normolipemic patients with peripheral vascular occlusive disease

VASA, 1986, Vol.15 (3), p.217

1986

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

128PD EGFR, KRAS, PIK3CA MUTATIONS AND RESPONSE TO TYROSINE KINASE INHIBITORS (TKIS) IN ADVANCED NSCLC PATIENTS

P1.01-65 Immune Gene Expression, Bayesian Network and Genetic Mutation Analysis in Advanced NSCLC Patients Treated with Immunotherapy

9081 A phase II retrospective trial of Carboplatin (CBDCA) and Alimta in refractory non-small cell lung cancer (NSCLC) with genetic polymorphisms analysis

9046 A phase II retrospective trial of Platinum/Gemcitabine (P/G)-based in first line treatment of advanced NSCLC with genetic polymorphisms analysis

9050 NSCLC in never smokers, a different disease – a single institution retrospective evaluation

9162 EGFR, KRAS, PIK3CA mutations and response to tyrosine kinase inhibitors (TKIs) in advanced NSCLC patients

6522 POSTER EGFR mutations and response to TKIs therapy in NSCLC patients pre-treated with chemotherapy

Interobserver reproducibility of immunohistochemical HER-2/neu assessment in human breast cancer : An update from INQAT round III

MYC and human telomerase gene (TERC) gene copy number gain in resected in non-small cell lung cancer (NSCLC)

Insulin-like growth factor receptor-1 (IGF1R) and epidermal growth factor receptor (EGFR) amplification and expression in surgically resected NSCLC

Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of MET, EGFR, KRAS, and PIK3CA mutations

Mutational analysis of KRAS, BRAF, and p53 genes in borderline and malignant epithelial ovarian tumors

Correlation of polymorphisms of genes involved in platinum/gemcitabine (P/G)-based metabolism with toxicity and clinical response in patients (pts) with advanced non-small cell lung cancer (NSCLC)

Effect of genetic polymorphisms on toxicity and survival in advanced non-small cell lung cancer (NSCLC) patients (pts) treated with carboplatin (CBDCA) and pemetrexed disodium regimen

HER2, EGFR, PIK3CA mutations in HER2+ metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T): Incidence and correlation with response

EGFR, KRAS, PIK3CA mutations and response to tyrosine kinase inhibitors (TKIs) in advanced NSCLC patients

Relevance of p53, bcl-2 and Rb expression on resistance to cisplatin-based chemotherapy in advanced non-small cell lung cancer

Evaluation of HER-2 in serum and tissue: correlation with clinical-pathological parameters and outcome in early stage breast cancer (BC) patients (pts)

Biological prognostic factors for early stage completely resected non-small cell lung cancer

PD-157 Serum EGFR in patients with non-small cell lung cancer(NSCLC) treated with gefitinib

O-112 Microsatellite alterations and P53 mutations in tumor and plasma DNA of resected non small cell lung cancer (NSCLC) patients. (A study of the Perugia Multidisciplinary team for thoracic tumors)

Arteriosclerotic Carotid Lesions in Hyperlipoproteinemia

p53 overexpression predicts the resistance to chemotherapy in advanced non small cell lung cancer (NSCLC)

Biological prognostic factors for early stage completely resected non-small cell lung cancer

HDL2- and HDL3-cholesterol in normolipemic patients with peripheral vascular occlusive disease

Aktive Filter

Suchergebnisse filtern